Orthopaedic Hemophilia Treatment Center: Goal and Objective

The goal of the Orthopaedic Hemophilia Treatment Center is to provide comprehensive, multidisciplinary care for persons with bleeding disorders and for the complications of those disorders, including full care for the blood transfusion transmitted disease.  The comprehensive, multidisciplinary treatment philosophy brings together hematologists, orthopaedic surgeons, nurses, social workers, and physical therapists to support patients and their families.  Adults and adolescents who have acquired blood-borne infections, including chronic hepatitis and HIV infection, through prior treatment with blood products, are also treated at the Center.

The objective of the Orthopaedic Hemophilia Treatment Center is the diagnosis and optimal management of bleeding disorders and their complications.  Disorders treated include hemophilia A and B, von Willebrand's disease, and other inborn deficiencies of plasma clotting factors and platelets.  The staff at the Orthopaedic Hemophilia Treatment Center understand that hemophilia is a serious, chronic, life-long disorder, and patients need more than purely medical management.  Bleeding can happen at any time, disrupting school or work, may cause prolonged periods of pain and disability, and decrease quality of life.  To assist patients at these times, the Center's social workers and counselors work with parents to help their children develop self-esteem and manage their disorder, and provide help allowing adults to live independently.  Further assistance is given to women from families affected by hemophilia who are at risk of being carriers via couseling and testing.

Connect With Us

Phone:
Tel (213) 742-1402

Toll Free (855) 340-5264
Fax:
(213) 742-1103


http://icons.iconarchive.com/icons/zerode/plump/24/Mail-icon.png Email Us


Street Address:
403 West Adams Blvd.,

Los Angeles, CA 90007 (map)


REFER A PATIENT (Fillable pdf)


APRIL NEWSLETTER



 

Ongoing Clinical Trials

  • My Life Our Future: A hemophilia Genotyping Initiative Data and Sample Research Repository
  • Evaluation of long-term safety and efficacy of Recombinant HCFactor VIII fusion protein
  • Phase I/II/III - Outcome study of Recombinant F.IX

Patient Stories

Go to top